FSKR yields 10.20% · ABBV yields 3.06%● Live data
📍 FSKR pulled ahead of the other in Year 1
Combined, FSKR + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FSKR + ABBV for your $10,000?
FS KKR Capital Corp. II, formerly known as FS Investment Corp II, is a business development company specializing in investments in floating rate, senior secured loans-first lien and second line, senior secured bonds, subordinated debt, collateralized securities, corporate bonds, debt securities, equity such as warrants or options in middle market private companies. The fund does not intend to invest to any significant degree in start-up companies, turnaround situations or companies with speculative business plans. It seeks to invest in various sectors such as consumer services, energy, capital goods, software and services, telecommunication services, consumer durables and apparel, diversified financials, materials, automobiles and components, commercial and professional services, media, technology hardware and equipment, health care equipment and services, insurance, retailing, transportation, pharmaceuticals, biotechnology, and life sciences, food and staples retailing, food, beverage, and tobacco, household and personal products, real estate, and utilities. The fund seeks to invest in private companies based in the United States. It also invests in non-U.S. securities, which may include securities denominated in U.S. dollars or in non-U.S. currencies, to the extent permitted by the 1940 Act. The fund purchase interests in loans through secondary market transactions in the ?over-the-counter? market for institutional loans or directly from our target companies. It also purchase minority interests in the form of common or preferred equity in target companies, either in conjunction with one of its debt investments or through a co-investment with a financial sponsor, such as an institutional investor or private equity firm. It may have board representation or board observation rights in its portfolio companies.
Full FSKR Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.